Biology and Therapeutic Targets of Colorectal Serrated Adenocarcinoma; Clues for a Histologically Based Treatment against an Aggressive Tumor
Open Access
- 14 March 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (6), 1991
- https://doi.org/10.3390/ijms21061991
Abstract
Serrated adenocarcinoma (SAC) is a tumor recognized by the WHO as a histological subtype accounting for around 9% of colorectal carcinomas. Compared to conventional carcinomas, SACs are characterized by a worse prognosis, weak development of the immune response, an active invasive front and a frequent resistance to targeted therapy due to a high occurrence of KRAS or BRAF mutation. Nonetheless, several high-throughput studies have recently been carried out unveiling the biology of this cancer and identifying potential molecular targets, favoring a future histologically based treatment. This review revises the current evidence, aiming to propose potential molecular targets and specific treatments for this aggressive tumor.Funding Information
- Instituto de Salud Carlos III (PI18/00144, PI15/00626)
This publication has 120 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapyTrends in Pharmacological Sciences, 2012
- HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progressionNature Reviews Cancer, 2011
- Immune Cells in Colorectal Cancer: Prognostic Relevance and Role of MSICancer Microenvironment, 2011
- Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinomaHistopathology, 2011
- Tricyclic antidepressants and the incidence of certain cancers: a study using the GPRDBritish Journal of Cancer, 2010
- Tumor-associated Macrophages (TAM) and Inflammation in Colorectal CancerCancer Microenvironment, 2010
- Migrastatin analogues target fascin to block tumour metastasisNature, 2010
- Cell adhesion and signalling by cadherins and Ig-CAMs in cancerNature Reviews Cancer, 2004
- The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapiesThe Journal of Pathology, 2002